GLP-1 receptor agonist use linked to lower mortality in seniors with cancer, T2D

GLP-1 receptor agonist use linked to lower mortality in seniors with cancer, T2D

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor (DPP4i) use, according to a study published online July 18 in JAMA Network Open.